Milicevic Z - Search Results

1

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.

Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Weinstock RS, et al. Among authors: milicevic z. Diabetes Obes Metab. 2015 Sep;17(9):849-58. doi: 10.1111/dom.12479. Epub 2015 May 20. Diabetes Obes Metab. 2015. PMID: 25912221 Free PMC article. Clinical Trial.

2

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Grunberger G, et al. Among authors: milicevic z. Diabet Med. 2012 Oct;29(10):1260-7. doi: 10.1111/j.1464-5491.2012.03745.x. Diabet Med. 2012. PMID: 22804250 Clinical Trial.

3

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Nauck M, et al. Among authors: milicevic z. Diabetes Care. 2014 Aug;37(8):2149-58. doi: 10.2337/dc13-2761. Epub 2014 Apr 17. Diabetes Care. 2014. PMID: 24742660 Free PMC article. Clinical Trial.

4

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).

Skrivanek Z, Gaydos BL, Chien JY, Geiger MJ, Heathman MA, Berry S, Anderson JH, Forst T, Milicevic Z, Berry D. Skrivanek Z, et al. Among authors: milicevic z. Diabetes Obes Metab. 2014 Aug;16(8):748-56. doi: 10.1111/dom.12305. Epub 2014 May 22. Diabetes Obes Metab. 2014. PMID: 24762094 Free article. Clinical Trial.

5

Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Nauck M, et al. Among authors: milicevic z. Diabetes Care. 2015 Mar;38(3):538. doi: 10.2337/dc15-er03. Diabetes Care. 2015. PMID: 25715416 Free PMC article. No abstract available.

6

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z. Blonde L, et al. Among authors: milicevic z. Lancet. 2015 May 23;385(9982):2057-66. doi: 10.1016/S0140-6736(15)60936-9. Lancet. 2015. PMID: 26009229 Clinical Trial.

7

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.

Milicevic Z, Anglin G, Harper K, Konrad RJ, Skrivanek Z, Glaesner W, Karanikas CA, Mace K. Milicevic Z, et al. Diabetes Obes Metab. 2016 May;18(5):533-6. doi: 10.1111/dom.12640. Epub 2016 Mar 4. Diabetes Obes Metab. 2016. PMID: 26847401 Clinical Trial.

8

Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.

Mari A, Del Prato S, Ludvik B, Milicevic Z, de la Peña A, Shurzinske L, Karanikas CA, Pechtner V. Mari A, et al. Among authors: milicevic z. Diabetes Obes Metab. 2016 Aug;18(8):834-9. doi: 10.1111/dom.12671. Epub 2016 May 16. Diabetes Obes Metab. 2016. PMID: 27059816

9

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.

Jendle J, Testa MA, Martin S, Jiang H, Milicevic Z. Jendle J, et al. Among authors: milicevic z. Diabetes Obes Metab. 2016 Oct;18(10):999-1005. doi: 10.1111/dom.12705. Epub 2016 Jul 22. Diabetes Obes Metab. 2016. PMID: 27279266 Clinical Trial.

10

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.

Nauck MA, Frossard JL, Barkin JS, Anglin G, Hensley IE, Harper KD, Milicevic Z. Nauck MA, et al. Among authors: milicevic z. Diabetes Care. 2017 May;40(5):647-654. doi: 10.2337/dc16-0984. Epub 2017 Mar 10. Diabetes Care. 2017. PMID: 28283565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters